{"brief_title": "Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis", "brief_summary": "OBJECTIVES: I. Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical, radiologic, and histologic parameters in patients with early stage primary sclerosing cholangitis.", "detailed_description": "PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of cladribine (2-chlorodeoxyadenosine; 2-CdA) for 5 consecutive days every month for 3 months.", "condition": "Cholangitis, Sclerosing", "intervention_type": "Drug", "intervention_name": "cladribine", "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Stage I-III primary sclerosing cholangitis Radiologically and pathologically documented No concomitant liver disease, e.g.: - Viral hepatitis - Autoimmune hepatitis - Primary biliary cirrhosis - Cirrhosis - Portal hypertension or associated complications - Jaundice caused by dominant stricture --Prior/Concurrent Therapy-- No concurrent immunosuppressives --Patient Characteristics-- Hematopoietic: - Absolute neutrophil count at least 2500/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin at least 10 g/dL Other: - No active infection - No fistula abscess - No active inflammatory bowel disease - Quiescent disease allowed, including: Chronic ulcerative colitis Crohn's disease - No other significant immunologic disorder - No active malignancy - No active alcohol or drug abuse - No pregnant or nursing women - Effective contraception required of fertile patients Endoscopic retrograde cholangiopancreatography within 36 months prior to registration Liver biopsy within 12 months prior to registration", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00004762.xml"}